PMID- 30711991
OWN - NLM
STAT- MEDLINE
DCOM- 20190220
LR  - 20201209
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 39
IP  - 2
DP  - 2019 Feb
TI  - Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in 
      Patients With Advanced/Recurrent Colorectal Cancer.
PG  - 1029-1034
LID - 10.21873/anticanres.13209 [doi]
AB  - AIM: This study aimed to clarify the tolerability of a trifluridine/tipiracil 
      combination tablet (TAS-102) in patients with advanced or recurrent colorectal 
      cancer over 75 years of age. PATIENTS AND METHODS: Patients were divided into 
      groups under the age of 75 years (n=62), and 75 years and over (n=17). The 
      treatment period with TAS-102 tablet, reasons for discontinuation, adverse events 
      (AEs), and overall survival (OS) were compared between the groups. RESULTS: The 
      incidence of AEs (including neutropenia, anemia, nausea, malaise, and anorexia) 
      was similar for both groups and the treatment enforcement periods for different 
      regimens were not statistically significant between the groups (p=0.207). No 
      major differences were observed in the reasons for discontinuation, such as AEs 
      or progressive disease, between the two groups. CONCLUSION: TAS-102 therapy for 
      advanced/recurrent colorectal cancer is considered to be highly tolerable in 
      patients 75 years and older. These findings are important for AE monitoring and 
      guidance for patients taking TAS-102.
CI  - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kimura, Michio
AU  - Kimura M
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Japan 
      kimkim0305nao@yahoo.co.jp.
FAU - Usami, Eiseki
AU  - Usami E
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Japan.
FAU - Teramachi, Hitomi
AU  - Teramachi H
AD  - Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
FAU - Yoshimura, Tomoaki
AU  - Yoshimura T
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Drug Combinations)
RN  - 0 (Pyrrolidines)
RN  - 0 (Tablets)
RN  - 0 (trifluridine tipiracil drug combination)
RN  - 56HH86ZVCT (Uracil)
RN  - QR26YLT7LT (Thymine)
RN  - RMW9V5RW38 (Trifluridine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia/chemically induced
MH  - Anorexia/chemically induced
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Colorectal Neoplasms/*drug therapy
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nausea/chemically induced
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local
MH  - Neutropenia/chemically induced
MH  - Pyrrolidines
MH  - Retrospective Studies
MH  - Tablets
MH  - Thymine
MH  - Treatment Outcome
MH  - Trifluridine/*adverse effects/*therapeutic use
MH  - Uracil/analogs & derivatives
OTO - NOTNLM
OT  - Elderly
OT  - TAS-102
OT  - advanced/recurrent colorectal cancer
OT  - tolerance
EDAT- 2019/02/04 06:00
MHDA- 2019/03/21 06:00
CRDT- 2019/02/04 06:00
PHST- 2018/12/14 00:00 [received]
PHST- 2019/01/18 00:00 [revised]
PHST- 2019/01/21 00:00 [accepted]
PHST- 2019/02/04 06:00 [entrez]
PHST- 2019/02/04 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
AID - 39/2/1029 [pii]
AID - 10.21873/anticanres.13209 [doi]
PST - ppublish
SO  - Anticancer Res. 2019 Feb;39(2):1029-1034. doi: 10.21873/anticanres.13209.